Related Experiment Video
Updated: Oct 12, 2025

Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant
Mayuresh M Abhyankar1, Barbara J Mann1, Jeffrey M Sturek2
1Department of Medicine, Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, 22903, USA.
Abstract:
We developed a SARS-CoV-2 spike subunit vaccine formulation containing dual TLR ligand liposome adjuvant. The vaccine-induced robust systemic neutralizing antibodies and completely protected mice from a lethal challenge. Two immunizations protected against lung injury and cleared the virus from lungs upon challenge. The adjuvanted vaccine also elicited systemic and local anti-Spike IgA which can be an important feature for a COVID-19 vaccine.
More Related Videos
12:53Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
Published on: March 16, 2022
08:07A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain
Published on: July 25, 2022